Patent: 9,617,336
✉ Email this page to a colleague
Summary for Patent: 9,617,336
Title: | C10RF32 antibodies, and uses thereof for treatment of cancer |
Abstract: | This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer. |
Inventor(s): | Cojocaru; Gady S. (Ramat Hasharon, IL), Rotman; Galit (Herzliyya, IL), Levine; Zurit (Herzliyya, IL), Dassa; Liat (Yehud, IL), Levi; Ofer (Moshav Mesilat Zion, IL), Briante; Raffaella (Burlingame, CA), Singh; Shweta (Fremont, CA), Watson; Susan R. (El Cerrito, CA), Pergam; Tania (Rishon LeZion, IL) |
Assignee: | COMPUGEN LTD (Holon, IL) |
Application Number: | 14/360,694 |
Patent Claims: | see list of patent claims |
Details for Patent 9,617,336
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2039-02-26 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2039-02-26 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |